Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Journal of Clinical Oncology · 2025-08 · 43 (22) · 2538-2549
DOI: 10.1200/jco-25-00166 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-08. Verfasst von Jeff P Sharman und 27 weiteren Autor:innen. Beteiligte Einrichtung: Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell, Pyrimidines, Agammaglobulinaemia Tyrosine Kinase. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted exclusively in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with cBTKi, and compared pirtobrutinib with investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR). METHODS Patients were randomly assigned 1:1 to receive pirtobrutinib (200 mg once daily) or IC of IdelaR or BR, and were stratified by previous use of venetoclax and del(17p). The primary end point was independent review committee–assessed progression-free survival (PFS). Secondary end points included time to next treatment or death (TTNT), overall survival (OS), and safety. The primary PFS end point was met at the time of the primary analysis (August 29, 2023), and updated results are reported from the final OS analysis (August 29, 2024). RESULTS A total of 238 patients were randomly assigned to receive pirtobrutinib (n = 119) or IC (n = 119; IdelaR [n = 82], BR [n = 37]). The PFS hazard ratio (HR) was 0.54 ([95% CI, 0.39 to 0.75]; P = .0002), with a median PFS of 14 months (95% CI, 11.2 to 16.6) in the pirtobrutinib group and 8.7 months (95% CI, 8.1 to 10.4) with IC. The unadjusted OS HR was 1.09 ([95% CI, 0.68 to 1.75]; P = .7202), and 18-month OS rate was 73.4% (95% CI, 63.9 to 80.7) in the pirtobrutinib group and 70.8% (95% CI, 60.9 to 78.7) with IC. Median TTNT was 24 months (95% CI, 17.8 to 29.7) with pirtobrutinib versus 10.9 months (95% CI, 8.7 to 12.5) with IC (HR, 0.37 [95% CI, 0.25 to 0.52]). At a median follow-up of 17.2 months, grade ≥3 treatment-emergent adverse events (AEs) were lower with pirtobrutinib (57.7%) than IC (73.4%). Treatment discontinuation due to AE occurred in 20 (17.2%) patients receiving pirtobrutinib and 38 (34.9%) patients receiving IC. CONCLUSION Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR.
- Department of Haematology, St James's University Hospital, Leeds, United Kingdom.
- Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland.
- Memorial Sloan Kettering Cancer Center NY, New York, NY.
- Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, Aurora, CO.
- Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
ORCID-Profile: Jeff P Sharman, Talha Munir, John M Burke, Norbert Grzasko, Alessandro Sanna, Ru Feng, Matthias Ritgen, Shuhua Yi, Francesc Bosch, Katherine Bao, Livia Compte, Paolo Ghia, Paul M Barr
Förderung
- NCI NIH HHS
Zitieren
APA
Sharman, J. P., Munir, T., Grosicki, S., Roeker, L. E., Burke, J. M., Chen, C. I., Grzasko, N., Follows, G., Mátrai, Z., Sanna, A., Qiu, L., Feng, R., Hua, V. M., Jurczak, W., Ritgen, M., Yi, S., Bosch, F., Coombs, C. C., Bao, K., …, & Barr, P. M. (2025). Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). Journal of Clinical Oncology, 43(22), 2538-2549. https://doi.org/10.1200/jco-25-00166
Vancouver
Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, et al. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). Journal of Clinical Oncology. 2025;43(22):2538-2549. doi:10.1200/jco-25-00166
BibTeX
@article{Sharman2025,
author = {Sharman, Jeff P and Munir, Talha and Grosicki, Sebastian and Roeker, Lindsey E and Burke, John M and Chen, Christine I and Grzasko, Norbert and Follows, George and Mátrai, Zoltán and Sanna, Alessandro and Qiu, Lugui and Feng, Ru and Hua, Vu Minh and Jurczak, Wojciech and Ritgen, Matthias and Yi, Shuhua and Bosch, Francesc and Coombs, Catherine C and Bao, Katherine and Patel, Vishalkumar and Liu, Bin and Compte, Livia and Guntur, Ananya and Wang, Denise Y and Hill, Marisa and Leow, Ching Ching and Ghia, Paolo and Barr, Paul M},
title = {Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {22},
pages = {2538--2549},
doi = {10.1200/jco-25-00166}
}
EUVIMED